Edition:
India

3SBio Inc (1530.HK)

1530.HK on Hong Kong Stock

12.54HKD
7:07am IST
Change (% chg)

HK$0.06 (+0.48%)
Prev Close
HK$12.48
Open
HK$12.54
Day's High
HK$12.56
Day's Low
HK$12.38
Volume
173,000
Avg. Vol
8,147,570
52-wk High
HK$19.80
52-wk Low
HK$8.21

Latest Key Developments (Source: Significant Developments)

3Sbio Inc Posts FY Net Profit Attributable Of RMB1,277.2 Mln
Wednesday, 20 Mar 2019 

March 20 (Reuters) - 3SBio Inc <1530.HK>::FY REVENUE INCREASED BY 22.7% TO APPROXIMATELY RMB4,583.9 MILLION.FY NET PROFIT ATTRIBUTABLE INCREASED BY 36.5% TO RMB1,277.2 MILLION.  Full Article

3SBio Inc Posts FY Net Profit Attributable RMB935.4 Mln
Monday, 26 Mar 2018 

March 26 (Reuters) - 3Sbio Inc <1530.HK>::FY NET PROFIT ATTRIBUTABLE RMB935.4 MILLION VERSUS RMB712.6 MILLION.RECOMMENDED PAYMENT OF FINAL DIVIDEND OF HKD6.85 CENTS PER ORDINARY SHARE.FY REVENUE UP 33.5% TO RMB3,734.3 MILLION.  Full Article

3Sbio Says Unit And Toray Sign Exclusive Licensing Agreement On Antipuritic Agent, TRK-820​
Monday, 15 Jan 2018 

Jan 15 (Reuters) - 3Sbio Inc <1530.HK>::UNIT AND TORAY ENTER EXCLUSIVE LICENSING AGREEMENT ON CERTAIN ORAL DISINTEGRATION TABLET FORMULATION OF ANTIPRURITIC DRUG TRK-820​.  Full Article

3SBio Says ‍China FDA Approves New Once-Weekly Bydureon To Improve Glycemic Control​
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - 3Sbio Inc <1530.HK>::‍CHINA FDA APPROVES NEW ONCE-WEEKLY BYDUREON TO IMPROVE GLYCEMIC CONTROL​.  Full Article

3SBio Inc says 601a approved by China FDA for clinical trials ​
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - 3SBio Inc <1530.HK>:Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials ​.  Full Article

REFILE-BRIEF-3SBio Inc Says Co Buys 3.4 Mln Shares For HK$32.9 Mln

* ON DEC 19, CO REPURCHASED 3.4 MILLION SHARES FOR AGGREGATE PURCHASE PRICE OF HK$32.9 MILLION Source text for Eikon: Further company coverage: